Repligen Corporation announced a $1 billion private offering of 0.25% Convertible Senior Notes due 2031, exchanging $456.8 million of existing 1.00% notes due 2028 and raising $458.6 million in cash. The new notes carry a conversion price with a 20% premium over recent stock prices, aiming to reduce interest expenses and extend debt maturity. Proceeds will partly repurchase shares and support working capital, acquisitions, and corporate growth. The transaction enhances Repligen's financial flexibility and supports its strategic focus on expanding bioprocessing capabilities and integrating recent acquisitions like BioLife.
Repligen's stock shows slight downward movement with a 0.08% decrease, trading at USD 188.49 on Pluang. As of Oct 30, 2026 17:11 WIB, the market cap stands at $11.98 billion with a 52-week high of $194.57 and a low of $102.87, while all recent order activity on Pluang is sell-side.
